ThermoGenesis Holdings, Inc. (THMO)
Market Cap | 4.39M |
Revenue (ttm) | 10.23M |
Net Income (ttm) | -10.49M |
Shares Out | 1.04M |
EPS (ttm) | -30.60 |
PE Ratio | n/a |
Forward PE | 2.28 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 243,082 |
Open | 4.05 |
Previous Close | 3.95 |
Day's Range | 3.96 - 4.54 |
52-Week Range | 2.67 - 40.95 |
Beta | 2.54 |
Analysts | Buy |
Price Target | 45.90 (+985.11%) |
Earnings Date | Mar 27, 2023 |
About THMO
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automa... [Read more]
Financial Performance
In 2021, THMO's revenue was $9.29 million, a decrease of -4.62% compared to the previous year's $9.74 million. Losses were -$11.38 million, -30.41% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for THMO stock is "Buy." The 12-month stock price forecast is $45.9, which is an increase of 985.11% from the latest price.
News

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement
RANCHO CORDOVA, Calif. , Jan. 11, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

ThermoGenesis Announces 1-for-45 Reverse Stock Split
RANCHO CORDOVA, Calif. , Dec. 21, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo...

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif. , Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and poi...

THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING
RANCHO CORDOVA, Calif. , Oct. 28, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

THERMOGENESIS PRICES $2.05 MILLION PUBLIC OFFERING
RANCHO CORDOVA, Calif. , Oct. 25, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-base...

ThermoGenesis Holdings to Present at the H.C. Wainwright 24th Annual Global Investment Conference
RANCHO CORDOVA, Calif. , Sept. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, ...

ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update
Driven by Sales of the AXP, Total Revenues for the Quarter Rose 38% Compared to Prior Year Conference Call to be Held Today at 12:00 p.m. PT/3:00 p.m.

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif. , Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and...

ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2022 and Provides Corporate Update
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif. , May 18, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and se...

ThermoGenesis Holdings Announces Year End 2021 Financial Results and Provides Corporate Update
Company Signs License Agreement With Boyalife Genomics and will Form TG Biosynthesis Division to Operate as CDMO for Cell and Cell-Based Gene Therapies Leases 35,475 SF To Be Built-Out as cGMP Complia...

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2021 and Provide a Corporate Strategic Update
Conference Call to be Held on March 28, 2022 RANCHO CORDOVA, Calif. , March 23, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools an...

ThermoGenesis Holdings to Hold Reconvened Annual Meeting of Stockholders on January 13, 2022
RANCHO CORDOVA, Calif., Jan. 11, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting") will re...

ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference
RANCHO CORDOVA, Calif., Jan. 10, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, t...

ThermoGenesis Holdings Announces Adjournment of Annual Meeting of Stockholders
RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company's Annual Meeting of Stockholders (the "Annual Meeting") scheduled for Thur...

Recap: ThermoGenesis Holdings Q3 Earnings
ThermoGenesis Holdings (NASDAQ:THMO) reported its Q3 earnings results on Friday, November 12, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2021, and Provides Corporate Update
RANCHO CORDOVA, Calif., Nov. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, t...

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide a Corporate Strategic Update
RANCHO CORDOVA, Calif., Nov. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, to...

ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ThermoGenesis Awarded NIH SBIR Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies
RANCHO CORDOVA, Calif., Sept. 14, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, ...

Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
RANCHO CORDOVA, Calif., Sept. 7, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, to...

ThermoGenesis Holdings, Inc. (THMO) Reports Q2 Loss, Tops Revenue Estimates
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -111.11% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the...

Recap: ThermoGenesis Holdings Q2 Earnings
Shares of ThermoGenesis Holdings (NASDAQ:THMO) decreased 2.7% after the company reported Q2 results. Quarterly Results Earnings per share rose 62.75% over the past year to ($0.38), which missed the es...